GART Recombinant Monoclonal Antibody

GART, also known as trifunctional purine biosynthetic protein adenosine-3, is a multifunctional enzyme that catalyzes three sequential steps in the de novo purine biosynthesis pathway. This metabolic pathway is essential for nucleotide production and is frequently upregulated in rapidly proliferating cells, making GART a protein of significant interest in cancer metabolism research, cell cycle studies, and investigations into metabolic reprogramming.

This recombinant monoclonal antibody, clone 7C11, offers the reproducibility and consistency that demanding research applications require. Generated using recombinant technology with a defined sequence, this antibody eliminates the lot-to-lot variability often encountered with traditional hybridoma-derived reagents, ensuring your experimental results remain comparable across extended studies.

Validation testing demonstrates reliable performance across multiple applications. In Western blot analysis, the antibody detects GART at an observed molecular weight of approximately 115 kDa, slightly higher than the predicted 108 kDa—a difference likely attributable to post-translational modifications such as glycosylation or phosphorylation. Detection has been confirmed in human cell lines including HT-29, Jurkat, and HeLa, as well as mouse NIH/3T3 cells, providing cross-species reactivity for comparative studies. For immunohistochemistry, the antibody has been validated in paraffin-embedded human breast cancer and liver tissue sections, delivering clear staining patterns suitable for tissue-based investigations.

The unconjugated format and affinity-purified preparation provide flexibility for integration into your existing detection systems. Whether you are exploring purine metabolism in oncology research, investigating cellular proliferation mechanisms, or characterizing metabolic enzyme expression patterns, this GART antibody delivers the specificity and consistency needed for meaningful experimental outcomes.